Picture4We are involved in a number of research collaborations with major pharmaceutical companies.  These range from early stage research establishing target tractability through to late lead optimisation programs. We value close co-operation with our collaborators to ensure the combined strengths of the partners are most effectively deployed to deliver drug candidates.

Current disclosed collaborations include

  • Servier, two development stage collaborations on Bcl-2 family of proteins and two further research collaborations on undisclosed oncology targets
  • Lundbeck, a research collaboration targetting LRRK2
  • Asahi Kasei Pharmaceuticals, a research collaboration targetting Rheumatoid Arthritis
  • Taisho Pharmaceuticals Co., Ltd, a research collaboration targetting an undisclosed target


Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

Read more ...

Product Pipeline

For more information on our pipeline, click below to visit Vernalis plc

Commercial Pipeline

Comm-thumbnailExplore the pipeline ...


NCE Pipeline

NCE-thumbnailExplore the pipeline ...


Contact Vernalis Research

T: (0)1223 895555
F: (0)1223 895556

Contact information
Maps and directions
Contact form

Fact Sheet

For more information on Vernalis, click on the below image to download a copy of our fact sheet

Vernalis Factsheet May 2015 Page 1